Slide 1: Q2 2026 Financial Results
Q2 2026 Financial Results As of June 30, 2026, reported on August 6, 2026 NASDAQ: JYNT | © 2026 The Joint Corp. All Rights Reserved. | 1
Slide 2: Safe Harbor Statements
Safe Harbor Statements This presentation contains statements about future events and expectations that constitute forward-looking statements. Forward-looking statements are based on our beliefs, assumptions and expectations of industry trends, our future financial and operating performance and our g
Slide 3: Sanjiv Razdan, CEO, President and Director
Sanjiv Razdan CEO, President and Director NASDAQ: JYNT | © 2026 The Joint Corp. All Rights Reserved. | 3
Slide 4: Joint 2.0
Joint 2.0 the first phase of our transformation journey is nearing completion, driving renewed growth and stronger profitability ✓ Operating as a capital-light, pure-play franchisor ✓ Driving higher profitability and stronger free cash flow conversion ✓ Significant improvement in our patient retenti
Slide 5: Q2 2026 Year-over-Year Improvements
Q2 2026 Year-over-Year Improvements $15.2M $1.5M $1.9M Revenue From Adjusted EBITDA From Free Continuing Operations Continuing Operations Cash Flow +14% +$1.4M +$1.6M Cash flow from operating activities grew 152% to $2.2M NASDAQ: JYNT | © 2026 The Joint Corp. All Rights Reserved. | 5
Slide 6: Refranchising Efforts
Refranchising Efforts • Southern California Bundle Ownership transferred for 32 clinics to date1, with 13 remaining clinics being operated by the buyer under Management Service Agreements • Northern California Bundle Signed Asset Purchase Agreement is in place for four clinics • Southeast Bundle Own
Slide 7: The Next Phase Of Our Journey
The Next Phase Of Our Journey Near Term ✓ Further strengthen new patient acquisition and win back lapsed patients ✓ Improve the patient experience ✓ Drive net new clinic growth and optimize current portfolio ✓ Elevate operations and development from recently acquired RD territories Longer Term ✓ Pri
Slide 8: Driving Top-Line Momentum
Driving Top-Line Momentum Messaging continues to be on chiropractic care for pain relief, and helping patients get back to what they love to do • Sequential improvement in active member growth each month this year • Increasing focus on our MVPs (most valuable patients) • SEO and AI visibility optimi
Slide 9: Comp Growth & Patient Retention
Comp Growth & Patient Retention • Q2 comp sales of (2.8)% improved compared to the first quarter • Comp sales expected to continue improving, throughout the second half of the year • Achieved best patient retention rate in over five years, driven by flexible membership options • Continuing to drive
Slide 10: Scott Bowman, Chief Financial Officer
Scott Bowman Chief Financial Officer NASDAQ: JYNT | © 2026 The Joint Corp. All Rights Reserved. | 10
Slide 11: Operating Metrics
Operating Metrics • $128.0M Q2 2026 System-wide Sales 1 (3.7)% vs Q2 2025 • (2.8)% Q2 2026 Comp Sales 2 140 basis-point improvement vs Q1 2026 • $3.2M Q2 2026 Consolidated Adjusted EBITDA In line with Q2 2025 1 System-wide sales include revenues at all clinics, whether operated or managed by the com
Slide 12: Second Quarter Results
Second Quarter Results 3 months ended 3 months ended $ in Millions 1 Difference 06/30/26 06/30/25 Revenue $15.2 $13.3 +$1.9 Cost of revenues $2.5 $2.8 ($0.3) Selling and marketing $4.9 $3.5 +$1.4 Depreciation and amortization $0.4 $0.4 $0.0 G&A $7.6 $7.7 ($0.1) Net loss from continuing operations 2
Slide 13: Strong Balance Sheet & Focused Capital Allocation
Strong Balance Sheet & Focused Capital Allocation $ in Millions 06/30/26 12/31/25 Unrestricted cash $22.2 $23.6 Restricted cash $1.7 $0.7 Availability on $20 Million JP Morgan Chase LOC $20.0 $20.0 • Repurchased approximately 82,000 shares for total consideration of approximately $677K, at an averag
Slide 14: Clinic Portfolio
Clinic Portfolio TOTAL CLINICS OPEN at quarter-end 967 960 935 941 Franchised 75 45 1 125 Company-owned or managed 838 135 126 706 96 579 513 64 442 60 399 885 896 370 48 800 842 47 312 61 712 246 47 610 4 515 453 352 394 265 309 242 175 82 12 26 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 202
Slide 15: A Starting Point for Higher Profitability
A Starting Point for Higher Profitability Post-Refranchising Initial / Short-Term Targets Enhanced Near-Term Profitability (est. mid-2026) Royalties & Fees Adj. EBITDA Margin Mid-2026 ~10% - 12% of System Sales 2024 2025 expected run rate Gross Margin 9% 12% ~19% - 21% ~83% - 85% of Revenue G&A Expe
Slide 16: Reiterating 2026 Financial Guidance
Reiterating 2026 Financial Guidance 2026 Financial Guidance 2025 Low High Actual System-wide Sales 1 ($ in Millions) $519 $552 $532.4 Comp Sales 2 (%) (3)% 3% (0.4)% Consolidated Adjusted EBITDA ($ in Millions) $12.5 $13.5 $13.0 New franchised clinic openings expected to be in range of 22 to 26, wit
Slide 17: Capital Allocation Priorities
Capital Allocation Priorities Investing In Growth Buy Back RD Share Initiatives Territories Repurchases NASDAQ: JYNT | © 2026 The Joint Corp. All Rights Reserved. | 17
Slide 18: Sanjiv Razdan, CEO, President and Director
Sanjiv Razdan CEO, President and Director NASDAQ: JYNT | © 2026 The Joint Corp. All Rights Reserved. | 18
Slide 19: Continued Progress on Reigniting Growth
Continued Progress on Reigniting Growth ✓ Y-o-Y Net Income and Adjusted EBITDA growth reflects the progress towards a capital-light, pure-play franchisor model ✓ Securing a strong foundation to launch The Joint 3.0 initiatives ✓ Capital allocation reflects conviction in long-term value of The Joint
Slide 20: Performance Metrics and Non-GAAP Measures
Performance Metrics and Non-GAAP Measures This presentation includes commonly discussed performance metrics. System-wide sales include revenues at all clinics, whether operated by the company or by franchisees. While franchised sales are not recorded as revenues by the company, management believes t
Slide 21: Quarterly GAAP – Non-GAAP Reconciliation
Quarterly GAAP – Non-GAAP Reconciliation Three Months Ended June 30, 2026 2025 From Continuing From Discontinued From Continuing From Discontinued Operations Operations Net Operations Operations Operations Net Operations Non-GAAP Financial Data: Net (loss) income $ (251,327) $ 904,348 $ 653,021 $ (9
Slide 22: Sanjiv Razdan, President & CEO
Sanjiv Razdan, President & CEO sanjiv.razdan@thejoint.com https://www.facebook.com/thejointchiro The Joint Corp. 16767 N. Perimeter Dr., Suite 110, Scottsdale, AZ 85260 | (480) 245-5960 @thejointchiro Scott Bowman, CFO scott.bowman@thejoint.com https://twitter.com/thejointchiro The Joint Corp. 16767